No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Biggest Stock Movers Tuesday: X, CYTK, and More
Cytokinetics Says European Regulator Validated Its Application for Cardiomyopathy Drug Candidate
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating
Express News | Cytokinetics Inc - FDA Sets Pdufa Target Action Date for Aficamten Nda as Sept 26, 2025
Express News | Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Truist Financial Sticks to Their Buy Rating for Cytokinetics (CYTK)